What: 2015 was a rough year to be a shareholders of TetraPhase Pharmaceuticals . All was going well until September, when the company released disappointing clinical news related to its lead compound, causing shares to plunge. The stock ended up losing 74% of its value during the year, according to data from S&P Capital IQ.
Continue Reading Below
So what:Results from the company's Phase 3 IGNITE2 clinical trial that did the company in. The trial was testing the company's next-generation antibiotic, called eravacycline, and its ability to treat complicated urinary tract infections. Although the drug performed well in earlier trials, it was unable to showstatistically significant non-inferiority when compared with levofloxacin, a currently available generic antibiotic.
Given that so much of this clinical-stage biopharma's value was tied to the future oferavacycline, the news sent shareholders heading for the exits en masse.
Now what: Sometimes bad things happen to even the most promising of clinical-stage biopharma companies.Just ask shareholders of Chimerix , another company that had a dreadful year. Chimerix announced that its lead compound, called brincidofovir, missed its primary endpoint in a pivotal phase 3 study, causing shares to plunge 80% in a single day.
Stocks such as Tetraphase Pharmaceuticals and Chimerixshould act as a reminder to all small-cap biopharmaceutical investors they are taking huge risks when they put money to work in these names, and that sometimes things can go very badly. It's for that reason that I continue to believe that if you choose to play in this arena, you diversify your holdings so that each company only represents a tiny amount of your totalportfolio. That way you can live to play another day if something goes horribly wrong.
The article Why Tetraphase Pharmaceuticals Dropped 74% of Its Value in 2015 originally appeared on Fool.com.
Continue Reading Below
Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.